Cardiogenic shock in myocardial infarction: Revascularization, mechanical support and pharmacotherapy;Infarktbedingter kardiogener schock: Revaskularisation, mechanische unterstützung und medikamentöse therapie

Deutsche Medizinische Wochenschrift

Volumn 133, Issue 48, 2008, Pages 2516-2521

  Buerke, M ^a   Russ M ^a   Werdan, K ^a  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

Author keywords

Cardiogenic shock; Mechanical support; Pharmacotherapy; Revascularization

Indexed keywords

CATECHOLAMINE; DOBUTAMINE; HYPERTENSIVE FACTOR; INOTROPIC AGENT;

AORTA BALLOON; CARDIOGENIC SHOCK; HEART ARRHYTHMIA; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEMODYNAMICS; HUMAN; REVASCULARIZATION; REVIEW;

CARDIOTONIC AGENTS; CATECHOLAMINES; HUMANS; INTRA-AORTIC BALLOON PUMPING; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; SHOCK, CARDIOGENIC;

EID: 57749110570     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1100950     Document Type: Review

References (36)

1. Anderson RD, Ohman EM, Holme Jr DR, Col J, Stebbins AL, Bates ER. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I Study. J Amer Coll Cardiol 1997; 30: 708-715
2. Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005; 294: 448-454
3. Brookes C, Ravn H, White P, Moeldrup U, Oldershaw P, Redington A. Acute right ventricular dilatation in response to ischemia significantly impairs left ventricular systolic performance. Circulation 1999; 100: 761-767
4. Burkhoff D, Cohen H, Brunckhorst C, O'Neill WW. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006; 152: 469 e1-e8
5. Cassidy SS, Mitchell JH. Effects of positive pressure breathing on right and left ventricular preload and afterload. Fed Proc 1981; 40: 2178-2181
6. Chen EW, Canto JG, Parsons LS et al. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation 2003; 108: 951-957
7. Christoph A, Prondzinsky R, Russ M, Janusch M, Schlitt A, Lemm H, Reith S, Werdan K, Buerke M. Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Cardiol Care 2008; 10: 49-57
8. Cotter G, Kaluski E, Milo O, Blatt A, Salah A, Hendler A, Krakover R, Golick A, Vered Z. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock. Eur Heart J 2003; 24: 1287-1295
9. Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol 2003; 18: 215-222
10. Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-1547
11. Delle Karth G, Buberl A, Geppert A et al. Hemodynamic effects of a continuous infusion of levosimendan in critically ill patients with cardiogenic shock requiring catecholamines. Acta Anaesthesiol Scand 2003; 47: 1251-1256
12. Fincke R, Hochman JS, Lowe AM, Menon V, Slater JN, Webb JG, LeJemtel TH, Cotter G. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol 2004; 44: 340-348
13. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510-524
14. Granger CB, Mahaffey KW, Weaver WD et al. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-1190
15. Hochman JS, Sleeper LA, Webb JG, Dzavik V, Buller CE, Aylward P, Col J, White HD. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA 2006; 295: 2511-2515
16. Hochman JS, Sleeper LA, Webb JG et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators: Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med 1999; 341: 625-634
17. Hochman JS, Boland J, Sleeper LA et al. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: Results of an International Registry. Circulation 1995; 91: 873-881
18. Jacobs AK, Leopold JA, Bates E et al. Cardiogenic shock caused by right ventricular infarction: a report from the SHOCK registry. J Am Coll Cardiol 2003; 41: 1273-n
19. Jolly S, Newton G, Horlick E et al. Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction. Amer J Cardiol 2005; 96: 1617-1620
20. Klein LW, Shaw RE, Krone RJ et al. Mortality after emergent percutaneous coronary intervention in cardiogenic shock secondary to acute myocardial infarction and usefulness of a mortality prediction model. Am J Cardiol 2005; 96: 35-41
21. Koreny M, Geppert A, Wutte M, Karth GD, Heinz G, Siostrzonek P. Effects of milrinone on pulmonary gas exchange in catecholamine-dependent heart failure. Amer J Cardiol 2000; 86: 570-573
22. Montalescot G, Barragan P, Wittenberg O et al, for the ADMIRAL Investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001; 344: 1895-1903
23. Ohman EM, Nanas J, Stomel RJ et al. Thrombolysis and counterpulsation to improve survival in myocardial infarction complicated by hypotension and suspected cardiogenic shock or heart failure: results of the TACTICS Trial. J Thromb Thrombolysis 2005; 19: 33-39
24. Picard MH, Davidoff R, Sleeper LA, Mendes LA, Thompson CR, Dzavik V, Steingart R, Gin K, White HD, Hochman JS. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock. Circulation 2003; 107: 279-284
25. Ramanathan K, Harkness SM, Nayar AC, Cosmi JE, Sleeper LS, White HD, Davidoff R, Hochman JS. Cardiogenic shock in patients with preserved left ventricular systolic function: characteristics and insight into mechanisms. Circulation 2004; 43: 241A
26. Russ MA, Prondzinsky R, Christoph A et al. Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 2007; 35: 2732-2739
27. Sanborn TA, Sleeper LA, Webb JG et al. Correlates of one-year survival in patients with cardiogenic shock complicating acute myocardial infarction: angiographic findings from the SHOCK trial. J Am Coll Cardiol 2003; 42: 1373-1379
28. Steg PG, Bonnefoy E, Chabaud S, Lapostolle F, Dubien PY, Cristofini P, Leizorovicz A, Touboul P. Impact of time to treatment on mortality after pre-hospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856
29. Tayara W, Starling RC, Yamani MH, Wazni O, Jubran F, Smedira N. Improved survival after acute myocardial infarction complicated by cardiogenic shock with circulatory support and transplantation: comparing aggressive intervention with conservative treatment. J Heart Lung Transplant 2006; 25: 504-509
30. Theroux P, Armstrong PW, Mahaffey KW et al. Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial. Eur Heart J 2005; 26: 1964-1970
31. Thiele H, Sick P, Boudriot E, Diederich KW, Hambrecht R, Niebauer J, Schuler G. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005; 26: 1276-1283
32. Urban PM, Freedman RJ, Ohman EM, Stone GW, Christenson JT, Cohen M, Miller MF, Joseph DL, Bynum DZ, Ferguson III JJ. In-hospital mortality associated with the use of intra-aortic balloon counterpulsation. Am J Cardiol 2004; 94: 181-185
33. Valente S, Lazzeri C, Vecchio S, Giglioli C, Margheri M, Bernardo P, Comeglio M, Chiocchini S, Gensini GF. Predictors of in-hospital mortality after percutaneous coronary intervention for cardiogenic shock. Int J Cardiol 2007; 114: 176-182
34. Yehudai L, Reynolds HR, Schwarz SA, Harkness SM, Picard MH, Davidoff R, Hochman JS. Serial echocardiograms in patients with cardiogenic shock: analysis of the SHOCK Trial. J Am Coll Cardiol 2006; 47 (suppl A): 111A-
35. Zeymer U, Vogt A, Zahn R, Weber MA, Tebbe U, Gottwik M, Bonzel T, Senges J, Neuhaus KL. Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI): results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J 2004; 25: 322-328
36. Zion MM, Balkin J, Rosenmann D, Goldbourt U, Reicher-Reiss H, Kaplinsky E, Behar S. Use of pulmonary artery catheters in patients with acute myocardial infarction. Analysis of experience in 5,841 patients in the SPRINT Registry. SPRINT Study Group. Chest 1990; 98: 1331-5